Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV Ferric Carboxymaltose vs Oral Iron for Anemia at Delivery in Tanzania
NCT02541708Phase 3Unknown
- Sponsor
- Ifakara Health Institute
- Start
- Sep 2015
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ferric carboxymaltose in iron deficiency anemia (IDA) (2 arms), sponsored by Ifakara Health Institute. Primary endpoint: Percentage of women with correction of hemoglobin to normal values (Hb> 11.5g/dl) at 6 weeks. Status: unknown.
02
Drugs
ferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT02541708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02541708.